Quantcast

Exclusive Perpetual Licenses - Apollon Patents & IP

Global Hemp Group has acquired the exclusive perpetual license for North America (the United States, Canada and Mexico) to certain Apollon Intellectual Property and proprietary technology, including, but not limited to, four key patents including any continuations, divisional, and continuations-in-part, along with any and all associated preclinical and clinical data relating to the patents and proprietary technology (the “IP”). The Exclusive Licensing has since been expanded for the two Composition patents listed below to include the European Union with extension to Morocco and Israel.

Pre-Clinical Validation of Cannabinoid and Mushroom Preparations for the Treatment of Cancer published January 31, 2024 on the Online Journal of Complementary & Alternative Medicine, an international peer review journal that aims to bring the ancient traditional methods to the world and its importance to the people.

Use of artificial intelligence - Apollon uses the latest state-of-the-art artificial intelligence techniques to optimize strain genetics for medical cannabis formulation development and to analyze patient genomic data to identify new potential biomarkers to triage patients into the correct treatment protocols.

AI plays a vital role in natural biologic drug discovery by accelerating the discovery process, improving efficiency, and enhancing the likelihood of success in developing new biologic drugs from natural sources. Specifically, AI has the ability to assist in natural biologic drug discovery in numerous ways including data analysis, predictive modeling, compound screening, target identification, and optimization of therapeutic agents. In addition, AI can analyze the results of high-throughput screening experiments to identify compounds with potential biological activity. By analyzing large datasets, AI algorithms can identify patterns and relationships that are often impossible for human researchers to identify, which allows for the correct selection of new novel drug candidates.

Apollon Formularies Plc is a UK-based international pharmaceutical company developing cancer treatments from natural biologics, including cannabinoids, functional mushrooms, psychedelic mushrooms and combinations of these compounds, which to date have shown successful independent, third-party results in pre-clinical testing. Apollon utilizes an artificial intelligence-based drug discovery platform.

Intellectual Property - Patent Information and Independent Test Data Being Licensed - The patents are registered under the International Patent System (PCT) and are also registered in Jamaica. This exclusive perpetual license will cover Canada, the United States, Mexico for all four patents, plus the European Union with extension to Morocco and Israel for the Composition patents and all associated supporting data, as listed below :

These patents include claims to the treatments of cancers and inflammatory conditions using natural biologics including compounds in medical cannabis, functional mushrooms, psychedelic mushrooms and combinations of these compounds that have been shown in independent, third-party preclinical 3D cell culture testing to kill cancer cells via direct cytotoxicity and immune stimulated cytotoxicity with great success and high efficacy. Under the Exclusive License Agreement, GHG will have the right to sublicense this intellectual property to legally licensed producers, and will initially focus on the United States (state by state where medicinal cannabis is legal) and Canada, allowing for the opportunity to generate near-term sublicensing revenue in these two countries.  

The Company is now engaged in discussions with legally licensed manufacturers, distributors and retail partners in the United States and Canada to monetize this IP by sublicensing it on both an exclusive and non-exclusive basis. To assist the Company in achieving this goal of creating an ongoing revenue stream, GHG has engaged Dr. Stephen D. Barnhill MD, creator of the IP and Chairman & CEO of Apollon, as Special Medical Advisor to the Company.

The Markets for the individual compounds used in the Apollon combinatorial pharmaceuticals are provided below.

Medical Cannabis

Data Bridge Market Research projected that the Medical Cannabis Market, which was US$11.0 Billion in 2021, would “rocket up to US$54.34 Billion by 2029”, and is expected to undergo a CAGR of 22.1% during the forecast period 2022 to 2029, with North America dominating the medical cannabis market.

The North American medical cannabis market is expected to gain market growth in the forecast period of 2021 to 2028. Data Bridge Market Research analyses that the market is growing at a CAGR of 25.0% in the forecast period of 2021 to 2028 and is expected to reach US$32.73 Billion by 2028. Increased medical use and legalization of cannabis is acting as a driver for the medical cannabis market.
Functional Mushrooms

The Global Functional Mushroom Market size was valued at US$8.45 Billion in 2021 and is projected to reach US$18.5 Billion by 2030, growing at a CAGR of 9.1% from 2022 to 2030 according to Data Bridge Market Research. The rise in awareness associated with the consumption of functional food and ingredients is expected to drive the market growth as well as the rise in demand for applications of functional mushrooms due to the growing healthcare benefit of mushrooms is also expected to drive the market growth. The North America functional mushroom market is expected to gain significant growth in the forecast period of 2022 to 2029. Data Bridge Market Research analyses that the market is growing with a CAGR of 6.2% in the forecast period of 2022 to 2029 and is expected to reach US$175 million by 2029.
Psychedelic Mushrooms

The Psychedelic Mushroom Market Size is estimated by Industry Arc to reach US$1.2 billion by 2027. Furthermore, it is poised to grow at a CAGR of 10.3% over the forecast period of 2022-2027. The psychedelic mushroom pharmaceutical applications segment held a dominant market share in the year 2021 and is estimated to grow with the fastest CAGR rate of 11.1% over the forecast period 2022-2027. The polyphyletic group of magic Mushrooms is mostly used for various mental disorders. Mostly treatment-resistant depression (TRD) and the latest potential therapy target major depressive disorder (MDD). TRD is estimated to affect about 5 million people in the U.S. at least 17 million American adults have MDD, which is more commonly referred to simply as “depression.” Depression is the leading cause of disability among Americans aged 15 to 44 and affects hundreds of millions of people globally, according to popular science. Such high potential of psilocybin mushrooms in pharmaceuticals helps to drive the psychedelic mushroom share over the forecast period 2022-2027.

The Psychedelic Mushroom Market based on Geography demonstrated that North America held a dominant market share of 36% in the year 2021. This is owing to the high burden of mental diseases and the growing demand for lysergic acid diethylamide drugs in this region. According to Mental Health America, 50 million adults suffered from mental illness in 2021 and 7.74% of adults in America reported having a substance use disorder in the past year. Also, the estimated number of adults with serious suicidal thoughts is over 11.4 million - an increase of 664,000 people from 2021. Such a high prevalence of mental disease in this region helps to grow the Psychedelic Mushroom Market Size in this region.